FDA
-
-
-
-
-
-
-
VIVUS (VVUS) Announces $11.55 Million Registered Direct Offering of Common Stock
-
-
-
-
-
-
-
VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
-
-
-
-
-
-
-
VIVUS Adopts Stockholder Rights Plan
-
-
-
-
-
-
-
VIVUS Reports Second Quarter 2019 Financial Results
-
-
-
-
-
-
-
VIVUS (VVUS) Commences Phase Four Safety and Efficacy Study of Qsymia in Obese Adolescents
-
-
-
-
-
-
-
Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism
-
-
-
-
-
-
-
VIVUS Announces 1-for-10 Reverse Stock Split
-
322,245 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

